Flash Finance

Trident Lifeline Ltd543616Corporate

Pharmaceuticals Latest results: Jun 2026 12 quarters of data
Consolidated Standalone
₹303.55
MCap ₹364 Cr · P/E 15.2
Trident Lifeline Ltd — Stock analysis & AI research Trident Lifeline Ltd — Multibagger AI analysis Trident Lifeline Ltd — Live exchange announcements
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹27 Cr
Sales · Jun 2026
+42.6% YoY
₹7 Cr
Operating Profit · Jun 2026
+46.4% YoY
26.9%
OPM % · Jun 2026
+2.7% YoY
₹5 Cr
Net Profit · Jun 2026
+44.2% YoY
₹4.26
EPS · Jun 2026
+40.6% YoY

📝 Trident Lifeline Ltd — results explained

Quarter ended June 2026 (Q1 FY27)

Trident Lifeline Ltd reported revenue of ₹27 crore for the quarter ended June 2026 (Q1 FY27), up 42.6% from ₹19 crore in the same quarter last year, and down 52.1% sequentially over the March 2026 quarter.

Net profit rose 44.2% year-on-year to ₹5 crore, from ₹3 crore. Earnings per share (EPS) came in at ₹4.26.

Operating profit stood at ₹7 crore — an operating margin (OPM) of 26.9%, compared with 26.2% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Trident Lifeline Ltd posted revenue of ₹126 crore, with a net profit of ₹22 crore.

On a trailing-twelve-month (TTM) basis, revenue stands at ₹134 crore with a net profit of ₹24 crore.

Valuation snapshot

At the current price of ₹303.55, 543616 has a market capitalisation of ₹364 crore and a trailing P/E of about 15.2.

Within the Pharmaceuticals industry, it is the 16th-largest of the 82 companies we track by market value.

Shareholding pattern

As of Jun 2026, promoters held 62.59%, foreign institutional investors (FIIs) 5.25%, domestic institutional investors (DIIs) 0.26%, public shareholders 31.90% of Trident Lifeline Ltd.

Promoter holding slipped from 62.86% to 62.59% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹364 Cr
Current Price ?
₹303.6
P/E ?
15.20below ind
Industry P/E ?
22.40
P/B ?
3.68
P/S ?
2.72
P/FCF ?
-52.04
Enterprise Value ?
₹389 Cr
EV/EBITDA ?
11.84
PEG ?
0.35
Earnings Yield ?
7.7%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹134 Cr
OPM ?
24.6%
Profit after tax (TTM) ?
₹24 Cr
EPS (TTM) ?
₹19.97
ROCE ?
26.0%
ROE ?
24.2%
ROA ?
15.1%
Growth
Sales — latest qtr ?
₹27 Cr
PAT — latest qtr ?
₹5 Cr
YoY qtr sales growth ?
42.6%
YoY qtr profit growth ?
44.2%
Sales growth (3y) ?
48%
Sales growth (5y) ?
60%
Profit growth (3y) ?
44%
Profit growth (5y) ?
96%
Financial Health
Debt ?
₹25 Cr
Debt to Equity ?
0.25
Interest Coverage ?
12.1
Current Ratio ?
N/A
Ownership
Promoter holding ?
62.59%
Change in promoter holding ?
-0.51%
Pledged percentage ?
N/A
Market
Return 3 months ?
21.4%
Return 6 months ?
23.8%

🗓️ Quarterly results (12 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Sep 2021Sep 2022Mar 2023Sep 2023Mar 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 81418102630371927245627 +42.6% -52.1%
Operating Profit 2242589566137 +46.4% -44.5%
Other Income 001011211131 -2.2% -82.4%
Interest 000000100110 +48.9% -50.8%
Depreciation 000000111111 +36.9% -30.2%
Profit Before Tax 2242699566147 +41.6% -53.2%
Net Profit 2242467354105 +44.2% -49.8%
EPS 4.322.523.471.493.435.575.783.034.263.368.114.26 +40.6% -47.5%
OPM % 25.0% 14.3% 22.2% 22.2% 19.2% 26.7% 24.3% 26.2% 23.3% 26.6% 23.2% 26.9% +2.7% +15.9%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric Prev FY FY26 TTM YoY %
Sales — ₹126 Cr ₹134 Cr —
Operating Profit — ₹31 Cr ₹33 Cr —
OPM % — 24.30% 24.55% —
NPM % — 17.81% 17.89% —
Other Income — ₹6 Cr ₹6 Cr —
Depreciation — ₹3 Cr ₹3 Cr —
Interest — ₹2 Cr ₹2 Cr —
EBIT — ₹28 Cr ₹30 Cr —
PBT — ₹31 Cr ₹33 Cr —
Tax — — ₹2 Cr —
Net Profit — ₹22 Cr ₹24 Cr —
EPS — ₹18.76 ₹19.99 —
Material Cost — — ₹16 Cr —
Employee Cost — — ₹1 Cr —
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 12121212 +0.0%
Reserves 34415487 +61.1%
Borrowings 361525 +66.7%
Other Liabilities 7141736 +111.8%
Total Liabilities 567398159 +62.2%
Fixed Assets 381529 +93.3%
CWIP 0410 -100.0%
Investments 441220 +66.7%
Other Assets 495770111 +58.6%
Total Assets 567398159 +62.2%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity -171-38 +366.7%
Cash from Investing Activity -6-11-8-20 -150.0%
Cash from Financing Activity 362714 +100.0%
Net Cash Flow 14-8-42 +150.0%
Free Cash Flow -19-8-9-7 +22.2%
CFO/OP -256%37%4%57% +1325.0%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 140112110177 +60.9%
Inventory Days 129137167136 -18.6%
Days Payable 879497153 +57.7%
Cash Conversion Cycle 183155180160 -11.1%
Working Capital Days 274246226192 -15.0%
ROCE % 25%19%28%26% -7.1%

👥 Shareholding (latest 4 periods)

Metric Sep 2025Dec 2025Mar 2026Jun 2026 % Chg
Promoters 63.10%64.11%62.86%62.59% -0.4%
FIIs 7.71%7.04%7.24%5.25% -27.5%
DIIs 0.41%0.35%0.27%0.26% -3.7%
Public 28.77%28.50%29.64%31.90% +7.6%
No. of Shareholders 554575607709 +16.8%

⚖️ Peer comparison

Industry: Pharmaceuticals · top 25 of 82 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SUDEEPPHRM Sudeep Pharma ₹1,033.30 11,671 63.3 675 184 34.6% 27.3% — — 26.6% 30.9%
2 SPARC Sun Pharma ₹185.08 6,006 3.8 1,909 1,584 84.7% 83.0% 2512.3% 553.9% 314.1% 59.9%
3 GUJTHEM Gujarat Themis ₹412.60 5,370 92.3 173 48 47.3% 27.8% 8.6% -6.1% 21.6% 23.0%
4 539997 Kwality Pharmaceuticals ₹2,652.10 3,525 34.0 553 81 24.4% 14.6% 35.7% 71.8% 46.3% 113.5%
5 524632 Shukra Pharmaceuticals ₹80.95 2,403 99.9 75 36 65.0% 48.2% 74.0% 130.1% 336.4% 1359.2%
6 FERMENTA Fermenta Biotech ₹475.00 1,362 21.4 501 64 18.9% 12.7% — — -17.9% -30.6%
7 506414 Fermenta Biotech ₹552.60 1,313 27.2 511 59 17.6% 11.5% 11.9% -6.6% -10.4% -56.7%
8 AHCL Anlon Healthcare ₹20.20 1,074 — — — — — — — 163.0% 133.3%
9 541096 Bharat Parenterals ₹1,525.00 1,062 — 323 -30 3.3% -9.3% 1.5% 37.5% -19.2% -309.6%
10 540737 Shree Ganesh ₹796.30 855 66.2 99 15 31.4% 15.6% 0.7% -23.0% -41.8% -67.5%
11 AMANTA Amanta Healthcare ₹197.75 768 52.5 291 15 20.4% 5.0% — — 5.4% -5.6%
12 539730 Fredun Pharmaceuticals ₹827.85 611 10.3 747 44 14.7% 5.9% 40.1% 90.0% 90.2% 88.1%
13 500422 Transchem Ltd-$ ₹38.00 474 10.8 — 4 — — -100.0% -17.8% -100.0% 186.3%
14 HALEOSLABS Haleos Labs ₹1,525.00 461 21.0 324 15 12.6% 4.7% -3.2% -4.9% -11.6% -58.0%
15 524731 Jenburkt Pharmaceuticals ₹865.75 404 11.6 170 33 23.6% 19.4% 11.8% 6.1% -1.4% -26.4%
16 543616 Trident Lifeline ₹279.85 364 14.0 134 24 24.6% 17.9% — — 42.6% 44.2%
17 512600 Astal Laboratories ₹75.00 308 32.3 170 10 8.8% 5.7% 142.9% -9.0% 56.0% 77.4%
18 524828 BDH Industries ₹336.80 300 16.6 100 12 15.3% 11.7% 44.3% 16.6% 20.2% 48.8%
19 500009 Ambalal Sarabhai ₹38.73 297 21.9 206 14 7.1% 6.6% 3.1% 261.1% 8.0% -51.6%
20 532039 Zenotech Laboratories ₹64.90 263 — 45 -3 17.0% -5.6% 1.3% -119.2% 10.1% -146.0%
21 531739 Gennex Laboratories ₹13.87 255 19.0 183 21 14.4% 11.3% 24.9% 15.5% 16.6% -6.9%
22 524790 Everest Organics ₹159.20 252 29.4 191 5 10.3% 2.8% 23.0% 527.7% -10.0% -21.1%
23 530163 Kerala Ayurveda ₹310.20 225 — 125 -26 -14.9% -20.8% 9.0% -16.8% -21.3% -477.8%
24 531569 Sanjivani Paranteral ₹199.95 214 32.7 66 7 15.3% 11.3% -7.6% -14.4% 8.8% 32.7%
25 524636 Oxygenta Pharmaceutical ₹32.25 195 — 135 -14 -5.9% -10.1% 3.3% -70.8% 144.5% 65.6%
❓ Frequently asked questions
What was Trident Lifeline Ltd's revenue in Q1 FY27?
Trident Lifeline Ltd reported revenue of ₹27 crore for the quarter ended June 2026 (Q1 FY27), up 42.6% from ₹19 crore in the same quarter last year, and down 52.1% sequentially over the March 2026 quarter.
What was Trident Lifeline Ltd's net profit in Q1 FY27?
Net profit rose 44.2% year-on-year to ₹5 crore, from ₹3 crore. Earnings per share (EPS) came in at ₹4.26.
What is 543616's market capitalisation and P/E ratio?
At the current price of ₹303.55, 543616 has a market capitalisation of ₹364 crore and a trailing P/E of about 15.2.
Who owns Trident Lifeline Ltd? (shareholding pattern)
As of Jun 2026, promoters held 62.59%, foreign institutional investors (FIIs) 5.25%, domestic institutional investors (DIIs) 0.26%, public shareholders 31.90% of Trident Lifeline Ltd.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI